Telo Genomics Corp Stock Today

TELO Stock  CAD 0.12  0.01  9.09%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Over 64

 
High
 
Low
Quite High
Telo Genomics is selling for under 0.12 as of the 18th of December 2024; that is 9.09% increase since the beginning of the trading day. The stock's lowest day price was 0.12. Telo Genomics has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of September 2024 and ending today, the 18th of December 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
Category
Healthcare
Classification
Health Care
Telo Genomics Corp., a personalized medicine company, focuses on the development and commercialization of predictive technological products. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. The company has 74.56 M outstanding shares of which 2.46 K shares are at this time shorted by private and institutional investors with about 0.07 days to cover all short positions. More on Telo Genomics Corp

Moving together with Telo Stock

  0.67TD Toronto Dominion BankPairCorr

Moving against Telo Stock

  0.81RY Royal BankPairCorr
  0.78BNS Bank of Nova ScotiaPairCorr
  0.76TD-PFD Toronto Dominion BankPairCorr
  0.73RY-PS Royal BankPairCorr
  0.7RY-PM Royal BankPairCorr
  0.66TD-PFI Toronto Dominion BankPairCorr

Telo Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Telo Genomics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Telo Genomics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
President CTO, MSc
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors)
Telo Genomics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Telo Genomics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Debt Levels
Telo Genomics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Telo Genomics' financial leverage. It provides some insight into what part of Telo Genomics' total assets is financed by creditors.
Liquidity
Telo Genomics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Telo Genomics Corp has accumulated 32.5 K in total debt. Telo Genomics Corp has a current ratio of 0.09, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Telo Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Telo Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Telo Genomics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Telo to invest in growth at high rates of return. When we think about Telo Genomics' use of debt, we should always consider it together with cash and equity.

Total Cash From Financing Activities

2.4 Million
Telo Genomics Corp (TELO) is traded on TSX Venture Exchange in Canada and employs 3 people. Telo Genomics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.2 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Telo Genomics's market, we take the total number of its shares issued and multiply it by Telo Genomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Telo Genomics Corp operates under Biotechnology sector and is part of Health Care industry. The entity has 74.56 M outstanding shares of which 2.46 K shares are at this time shorted by private and institutional investors with about 0.07 days to cover all short positions. Telo Genomics Corp has accumulated about 24.25 K in cash with (2.63 M) of positive cash flow from operations.
Check Telo Genomics Probability Of Bankruptcy
Ownership Allocation
Telo Genomics Corp shows a total of 74.56 Million outstanding shares. Telo Genomics Corp has 5.34 % of its outstanding shares held by insiders and 2.74 % owned by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Telo Ownership Details

Telo Genomics Corp Risk Profiles

Although Telo Genomics' alpha and beta are two of the key measurements used to evaluate Telo Genomics' performance over the market, the standard measures of volatility play an important role as well.

Telo Stock Against Markets

Be your own money manager

Our tools can tell you how much better you can do entering a position in Telo Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Sign In To Macroaxis Now

   

Sign In To Macroaxis

Sign in to explore Macroaxis' wealth optimization platform and fintech modules
All  Next Launch Module

Telo Genomics Corporate Executives

Elected by the shareholders, the Telo Genomics' board of directors comprises two types of representatives: Telo Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Telo. The board's role is to monitor Telo Genomics' management team and ensure that shareholders' interests are well served. Telo Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Telo Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Sabine MaiInterim FounderProfile

Additional Tools for Telo Stock Analysis

When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.